Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?
Executive Summary
Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.
You may also be interested in...
Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures
Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation
As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.